Welcome to our dedicated page for Palisade Bio SEC filings (Ticker: PALI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Palisade Bio’s regulatory paperwork is not for the faint-hearted. The company’s 10-K packs dense discussions about cash runway, clinical-trial risk and intestinal-barrier science, while each 8-K can shift sentiment overnight. If you’ve ever wondered “where can I find Palisade Bio’s quarterly earnings report 10-Q filing?” or tried to follow a sudden share offer buried in an S-1, you know the challenge. Stock Titan’s AI-powered analysis puts those worries to rest.
Our AI summaries deliver Palisade Bio SEC filings explained simply. See R&D spend trends in the latest Palisade Bio quarterly earnings report 10-Q filing, catch every Palisade Bio 8-K material events explained, and monitor Palisade Bio insider trading Form 4 transactions in real time. Whether you need the Palisade Bio annual report 10-K simplified or Palisade Bio proxy statement executive compensation details, one click reveals plain-English insights, key tables and cross-document links.
Because pipeline progress drives valuation, investors track dilution risk, milestone payments and executive incentives. Our dashboard alerts you to Palisade Bio Form 4 insider transactions real-time, flags new at-the-market offerings, and highlights how fresh trial data could affect funding needs. Stop opening dozens of PDFs—understanding Palisade Bio SEC documents with AI means you get answers faster: Is management buying or selling? How long does cash last? What happens if the Phase 2 readout slips? Stock Titan delivers the Palisade Bio earnings report filing analysis you need—faster than the market.
Palisade Bio, Inc. (Nasdaq: PALI) filed an 8-K on July 9, 2025 covering recent board changes. Director Margery Fischbein resigned effective July 2, 2025; the company states the resignation was not due to any disagreement with management or policies. The board fully accelerated the vesting of Ms. Fischbein’s remaining 3,100 stock options and preserved their original expiration dates.
To fill the vacancy, the board elected Dr. Emil Chuang, MB BS FRACP on July 7, 2025. Dr. Chuang was deemed an independent director and immediately joined the Audit, Compensation, and Governance & Nominating Committees. In line with the non-employee director compensation policy, he will receive an option to purchase 8,000 shares at the market closing price on the grant date and standard cash/equity fees disclosed in the 2024 proxy. The company will also execute its standard indemnification agreement with Dr. Chuang.
A press release announcing the appointment (Exhibit 99.2) accompanied the filing. No other operational or financial metrics were disclosed.
FAQ
What is the current stock price of Palisade Bio (PALI)?
What is the market cap of Palisade Bio (PALI)?
What is the core focus of Palisade Bio Inc?
Which medical conditions does the company target?
How does Palisade Bio Inc generate revenue?
What sets the company apart from its competitors?
What stage of development is Palisade Bio Inc currently in?
How does the company contribute to advancements in healthcare?
What are the main components of its research pipeline?
